Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy.
about
The influence of riboflavin photochemistry on plasma coagulation factorsComparative lytic efficacy of rt-PA and ultrasound in porcine versus human clotsA randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura.Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development.Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura.Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center ExperienceUniversal pathogen-reduced plasma in elective open-heart surgery and liver resection.Levels of factor VIII and factor IX in fresh-frozen plasma produced from whole blood stored at 4 °C overnight in Turkey.Virus-inactivated plasma - Plasmasafe: a one-year experienceRecommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasmaA study of the quantity of some stable and labile coagulation factors in fresh-frozen plasma produced from whole blood stored for 24 hours in IranRecommendations for the transfusion of plasma and platelets.A biochemical quality study of a pharmaceutically licenced coagulation active plasma (Octaplas) thawed by the SAHARA-III dry tempering system compared to the regular use of a water bath.Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products.Coagulation profile of liquid-state plasma.
P2860
Q24614152-987D817E-EBE3-43D6-BE5F-0BA42E686263Q30355737-5A8B8DEC-9DA0-4AB0-8459-0DC62BE3E04CQ30441694-6C0EEEC6-BBDD-4145-9FEC-B4FF65CF8066Q33360121-6BF658A3-3740-45EF-894C-E72EBA616162Q33368173-6B0D59A3-38B9-4C01-B7BF-4EF5F3EE603AQ33374478-92D205C9-E48F-4324-A358-AA9C6F943E32Q33376161-FA9D3191-8F44-4485-B6FE-15AB0EF2BB9FQ34038164-2E494C6C-8E2F-4A63-8538-6A008CF6E1DFQ35040142-F7E7B333-E560-4634-BF9B-925991BE86E7Q35874051-CD360AA0-7418-49A9-9196-31FF0F9BBFC8Q36874269-FE119BC5-DE8E-486A-802A-6091B20BE405Q37062415-C4AB94E8-3483-4858-8628-D30E44605C40Q37119689-06BF5305-26C4-4893-AEE0-FFF6E9591354Q37209117-DE646A6B-B18E-4854-BE5E-CC2D350ED86FQ39062310-12BEBD84-5016-42CD-AD91-61EC51B42FEFQ40284794-CCF3825C-6191-4FE8-B9B6-E0FB42266F1DQ45979592-EB06CD36-7BA5-48AA-BE6D-2723A19E2F5F
P2860
Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Manufacture and composition of ...... tion and therapeutic efficacy.
@ast
Manufacture and composition of ...... tion and therapeutic efficacy.
@en
Manufacture and composition of ...... tion and therapeutic efficacy.
@nl
type
label
Manufacture and composition of ...... tion and therapeutic efficacy.
@ast
Manufacture and composition of ...... tion and therapeutic efficacy.
@en
Manufacture and composition of ...... tion and therapeutic efficacy.
@nl
prefLabel
Manufacture and composition of ...... tion and therapeutic efficacy.
@ast
Manufacture and composition of ...... tion and therapeutic efficacy.
@en
Manufacture and composition of ...... tion and therapeutic efficacy.
@nl
P1433
P1476
Manufacture and composition of ...... tion and therapeutic efficacy.
@en
P2093
Hannelore Haubelt
Peter Hellstern
P356
10.1016/S0049-3848(02)00145-7
P478
107 Suppl 1
P577
2002-10-01T00:00:00Z